Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do genes drive heart damage from irregular rhythms?

NCT ID NCT06896266

Knowledge-focused Sponsor: Hospital Universitario 12 de Octubre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are studying people with arrhythmia-induced cardiomyopathy, a condition where a fast or irregular heartbeat weakens the heart muscle. The study checks whether these patients carry more harmful gene variants than people with other types of cardiomyopathy or the general population. It also tracks whether those genetic findings relate to future heart failure hospitalizations or returning arrhythmias. About 109 participants with atrial fibrillation or atrial flutter and reduced heart pumping function take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers find a genetic link, it could help doctors identify which patients with irregular heart rhythms are most likely to develop heart muscle weakness and guide closer monitoring.
What could go wrong
This is an observational study, so it can show associations but not prove cause and effect. Genetic findings in this group may not apply to other patients, and the results may not change treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 109 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with clinical suspected arrhythmia-induced cardiomyopathy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of atrial fibrillation or atrial flutter not self-limited. * Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \<50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \<50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%. * Signature of informed consent. * Ability to understand and accept participation in the study. Exclusion Criteria: * Refusal of informed consent. * Legal or juridical incapacity. * Age \<18 years. * Life expectancy less than 1 year. * Impossibility of a follow-up of at least 6 months. * Presence of a ventricular rate \>140 beats per minute, limiting the validity of imaging measurements. * Presence of known factors causing systolic ventricular dysfunction: * Prior cardiomyopathy diagnosis. * Severe mitral or aortic valve disease. * Non-revascularizable ischemic heart disease. * Context of peri-resuscitation cardiopulmonary care. * Abusive alcohol consumption, defined as \>80 grams of ethanol or \>7 standard alcoholic beverages per day. * Active treatment with chemotherapeutic agents or radiation therapy to the thorax. * Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation atrial flutter cardiac rhythm disease cardiomyopathy heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrhythmia Arrhythmia-induced cardiomyopathy (AICM) Cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 12 de Octubre University Hospital

    RECRUITING

    Madrid, Madrid, 28004, Spain

  • Albacete University Hospital Complex

    NOT_YET_RECRUITING

    Albacete, Spain

  • Ciudad Real General University Hospital

    RECRUITING

    Ciudad Real, Castille-La Mancha, 15004, Spain

  • Ramón y Cajal University Hospital

    ACTIVE_NOT_RECRUITING

    Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.